Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.20 USD

201.20
7,194,067

-0.48 (-0.24%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $201.20 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $159.59, marking a -0.99% move from the previous day.

FDA Expands AbbVie's (ABBV) Qulipta Label in Chronic Migraine

Following FDA's label-expansion approval, AbbVie's (ABBV) Qulipta is the first and the only oral CGRP receptor antagonist approved to prevent episodic and chronic migraines.

Lilly's (LLY) Ulcerative Colitis Candidate Gets CRL from FDA

The FDA rejects Eli Lilly's (LLY) regulatory filing seeking approval for mirikizumab to treat ulcerative colitis indication, citing issues related to the drug's proposed manufacturing.

J&J (JNJ) to Initiate Q1 Earnings Season for Pharma Sector

Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Rejects LLY's Mirikizumab, NVO Ups 2023 Sales & Profit View

FDA issues CRL to Eli Lilly's (LLY) BLA seeking approval of mirikizumab for ulcerative colitis (UC). Novo Nordisk (NVO) ups sales and profit outlook for 2023.

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, NextEra Energy, The Boeing and Canadian Natural Resources

JPMorgan Chase, AbbVie, NextEra Energy, The Boeing and Canadian Natural Resources are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Research Reports for JPMorgan Chase, AbbVie & NextEra Energy

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and NextEra Energy, Inc. (NEE).

Why AbbVie (ABBV) Could Beat Earnings Estimates Again

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AbbVie (ABBV) Stock Moves 0.06%: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $161.38, moving +0.06% from the previous trading session.

AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica

AbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two blood cancer treatments is based on confirmatory studies data that do not support full approval.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

Smart Beta ETF report for NOBL

Johnson & Johnson (JNJ) Soars 4.5%: Is Further Upside Left in the Stock?

Johnson & Johnson (JNJ) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed at $160.42 in the latest trading session, marking a +0.66% move from the prior day.

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $157.54, marking a -0.3% move from the previous day.

The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly

Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog.

AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs

AbbVie???s (ABBV) two studies evaluating Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus meet their primary endpoints.

Kinjel Shah headshot

Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL

Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951

AbbVie (ABBV) Gets FDA Rejection for Parkinson's Candidate

In the CRL, the FDA asks AbbVie (ABBV) for some extra information about the pump device used to administer the Parkinson's disease medicine, ABBV-951.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Here's What is Driving Amgen (AMGN) Stock's Outperformance

Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $156.12, marking a +1.23% move from the previous day.